Last viewed:
MRTX
Prices are updated after-hours
MRTX
|
$58.7
-0.17%
0.34%
0
|
Health Technology
(0.0% 1d)
(0.0% 1m)
(43.1% 1y)
(0.0% 2d)
(-0.1% 3d)
(0.0% 7d)
(-41.54%
volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 4,117,670,342
http://www.mirati.com
Sec
Filling
|
Patents
| 111 employees
(US) Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
cancer
immunology
genetic
add to watch list
Paper trade
email alert is off
Press-releases
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
Published: 2024-02-02
(Crawled : 14:30)
- biospace.com/
RYZB
|
$62.49
0.03%
280K
|
| 0.64%
| O: 0.03%
H: 0.11%
C: 0.0%
XYF
|
$3.78
0.0%
5.6K
|
Finance
| -1.55%
| O: 1.04%
H: 1.79%
C: -1.23%
BMY
|
$48.93
1.3%
0.0%
10M
|
Health Technology
| -0.76%
| O: 1.23%
H: 1.5%
C: -1.14%
KRTX
|
$329.83
0.0%
1.9M
|
Health Technology
| 5.24%
| O: 0.06%
H: 0.0%
C: 0.0%
financial
results
Corcept Appoints Roberto Vieira as President, Oncology
Published: 2024-01-29
(Crawled : 13:00)
- globenewswire.com
CORT
|
$22.97
1.37%
1.35%
920K
|
Health Technology
| 7.99%
| O: 0.6%
H: 2.48%
C: 2.48%
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
Published: 2024-01-23
(Crawled : 14:30)
- biospace.com/
MS
|
News
0
d
|
$90.66
0.44%
0.07%
8.1M
|
Finance
| 5.77%
| O: -0.07%
H: 1.38%
C: 1.25%
EVR
|
$186.36
0.58%
0.0%
290K
|
Finance
| 5.36%
| O: 0.35%
H: 0.29%
C: -0.26%
BMY
|
$48.93
1.3%
0.0%
10M
|
Health Technology
| -2.56%
| O: 0.22%
H: 1.49%
C: 0.89%
acquisition
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Published: 2024-01-10
(Crawled : 13:00)
- prnewswire.com
MRTX
|
$58.7
-0.17%
0.34%
0
|
Health Technology
| -0.31%
| O: 0.02%
H: 0.17%
C: -0.19%
krasg12
lung
cancer
cell
treatment
advanced
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10
(Crawled : 12:30)
- prnewswire.com
BMY
|
$48.93
1.3%
0.0%
10M
|
Health Technology
| -4.19%
| O: 0.4%
H: 0.18%
C: 0.0%
MRTX
|
$58.7
-0.17%
0.34%
0
|
Health Technology
| 4.61%
| O: -0.11%
H: 0.0%
C: 0.0%
krasg12
lung
chmp
positive
cancer
cell
treatment
therapeutics
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-07
(Crawled : 21:00)
- globenewswire.com
GNMSF
|
$290.38
3.83%
220
|
Health Technology
| -3.35%
| O: 6.62%
H: 2.29%
C: -0.06%
ZLAB
|
$14.08
-0.99%
-0.99%
470K
|
Health Technology
| -52.14%
| O: 8.3%
H: 0.02%
C: -2.12%
SGEN
|
$228.74
0.1%
20M
|
Health Technology
| 6.91%
| O: 0.49%
H: 0.0%
C: -0.57%
NVCR
|
$12.09
0.33%
0.33%
850K
|
Health Technology
| -6.37%
| O: 0.7%
H: 0.0%
C: -6.94%
MRTX
|
$58.7
-0.17%
0.34%
0
|
Health Technology
| 4.89%
| O: 0.29%
H: 0.21%
C: -0.48%
KRTX
|
$329.83
0.0%
1.9M
|
Health Technology
| 83.73%
| O: 0.27%
H: 0.14%
C: -3.34%
GMAB
|
$28.72
1.38%
1.36%
360K
|
Health Technology
| -3.35%
| O: 7.35%
H: 0.44%
C: -2.18%
results
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-06
(Crawled : 15:00)
- biospace.com/
BMY
|
$48.93
1.3%
0.0%
10M
|
Health Technology
| -8.56%
| O: 0.61%
H: 0.77%
C: -0.66%
MRTX
|
$58.7
-0.17%
0.34%
0
|
Health Technology
| 5.6%
| O: 0.75%
H: 0.59%
C: 0.27%
therapeutics
financial
results
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
Published: 2023-11-02
(Crawled : 12:00)
- globenewswire.com
BMY
|
$48.93
1.3%
0.0%
10M
|
Health Technology
| -5.81%
| O: -0.9%
H: 1.08%
C: 0.61%
MRTX
|
$58.7
-0.17%
0.34%
0
|
Health Technology
| 5.41%
| O: 0.2%
H: 0.43%
C: -0.38%
KURA
|
$17.55
-0.74%
-0.74%
1.3M
|
Health Technology
| 125.16%
| O: 0.13%
H: 6.0%
C: 5.25%
ko-2806
collaboration
therapeutics
agreement
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
Published: 2023-10-31
(Crawled : 06:00)
- biospace.com/
MS
|
News
0
d
|
$90.66
0.44%
0.07%
8.1M
|
Finance
| 29.31%
| O: 0.83%
H: 0.0%
C: 0.0%
BMY
|
$48.93
1.3%
0.0%
10M
|
Health Technology
| -5.76%
| O: 0.25%
H: 0.54%
C: 0.29%
MRTX
|
$58.7
-0.17%
0.34%
0
|
Health Technology
| 6.12%
| O: 0.46%
H: 0.0%
C: 0.0%
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Published: 2023-10-26
(Crawled : 13:00)
- biospace.com/
XYF
|
$3.78
0.0%
5.6K
|
Finance
| -3.06%
| O: -3.19%
H: 4.87%
C: 4.87%
BMY
|
$48.93
1.3%
0.0%
10M
|
Health Technology
| -14.68%
| O: -4.68%
H: 2.46%
C: -1.83%
MRTX
|
$58.7
-0.17%
0.34%
0
|
Health Technology
| 6.54%
| O: 0.16%
H: 0.47%
C: 0.2%
financial
results
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount